|
|
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yin198716: 金币+15, 翻译EPI+1, ★有帮助 2013-04-08 17:15:02
Tumor angiogenesis is essential for tumor growth and metastasis and is triggered by a variety of proangiogenic factors, regulated by many angiogenic pathways.
肿瘤血管新生是肿瘤生长和转移所必需的，它由多种促血管形成因子触发并受多种血管新生通路调控。
The most important and best characterized is the VEGF pathway .
最重要和最有特点的就是VEGF通路。
Blockade of VEGF signaling inhibits tumor angiogenesis and growth in various preclinical models and having systemic effects .
在多种临床前模型中，阻断VEGF信号会抑制肿瘤血管新生和肿瘤生长，并且会有系统性的效应。
The effect of anti-VEGF strategy has been validated in randomized phase III clinical trials.
抗VEGF策略的作用在随机III期临床试验中得到巩固。
Disruption of VEGF signaling by using bevacizumab, a humanized anti-human VEGF antibody or sorafenib and sunitinib, 2 small chemical inhibitors of receptor-tyrosine kinases (RTK) including VEGF receptors have yielded a significant improvement in progression-free survival but rarely in overall survival for patients with several types of cancers including metastatic colorectal cancer , advanced non–small cell lung cancer , metastatic breast cancer , advanced clear-cell renal-cell carcinoma and advanced hepatocellular carcinoma .
用贝伐单抗（人源化的抗VEGF抗体）或用索拉非尼和舒尼替尼（受体络氨酸激酶的两种化学抑制剂）
破坏VEGF信号，可以显著改善无进展生存期，但对同时患有多种癌症病人的总体存活率的改善并不大，包括转移性结直肠癌、晚期非小细胞肺癌、转移性乳腺癌、晚期透明性肾细胞癌和晚期肝癌。
收录到淘贴专辑 |
|
回复此楼